Literature DB >> 17725496

Involvement of prelamin A in laminopathies.

N M Maraldi1, G Lattanzi.   

Abstract

The precursor protein of the nuclear lamina constituent lamin A is a 74-kDa protein called prelamin A which undergoes subsequent steps of posttranslational modification at its C-terminal CaaX residue. The unexpected finding that accumulation of unprocessable prelamin A is the molecular basis of the most severe laminopathies so far identified, including Hutchinson-Gilford progeria and restrictive dermopathy, has opened new perspectives in the study of the pathogenic mechanisms causing all lamin A/C-linked disorders, as well as new interest in the analysis of molecular mechanisms regulating prelamin A processing. However, complete knowledge of the cellular pathways affected downstream of prelamin A accumulation is still lacking, but it could give new insights both in normal and pathogenic mechanisms regulated by lamins. In this article, we review the involvement of defects of prelamin A processing in the pathogenesis of a group of laminopathies. In particular, we discuss the possibility that mutations leading to accumulation of particular forms of prelamin A result in specific nuclear abnormalities and impairment of nuclear functions leading to cell senescence or altered metabolism.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17725496     DOI: 10.1615/critreveukargeneexpr.v17.i4.50

Source DB:  PubMed          Journal:  Crit Rev Eukaryot Gene Expr        ISSN: 1045-4403            Impact factor:   1.807


  7 in total

1.  Prelamin A-mediated recruitment of SUN1 to the nuclear envelope directs nuclear positioning in human muscle.

Authors:  E Mattioli; M Columbaro; C Capanni; N M Maraldi; V Cenni; K Scotlandi; M T Marino; L Merlini; S Squarzoni; G Lattanzi
Journal:  Cell Death Differ       Date:  2011-02-11       Impact factor: 15.828

2.  Altered chromatin organization and SUN2 localization in mandibuloacral dysplasia are rescued by drug treatment.

Authors:  Daria Camozzi; Maria Rosaria D'Apice; Elisa Schena; Vittoria Cenni; Marta Columbaro; Cristina Capanni; Nadir M Maraldi; Stefano Squarzoni; Michela Ortolani; Giuseppe Novelli; Giovanna Lattanzi
Journal:  Histochem Cell Biol       Date:  2012-06-17       Impact factor: 4.304

3.  Familial partial lipodystrophy, mandibuloacral dysplasia and restrictive dermopathy feature barrier-to-autointegration factor (BAF) nuclear redistribution.

Authors:  Cristina Capanni; Stefano Squarzoni; Vittoria Cenni; Maria Rosaria D'Apice; Alessandra Gambineri; Giuseppe Novelli; Manfred Wehnert; Renato Pasquali; Nadir M Maraldi; Giovanna Lattanzi
Journal:  Cell Cycle       Date:  2012-08-30       Impact factor: 4.534

4.  Rapamycin treatment of Mandibuloacral dysplasia cells rescues localization of chromatin-associated proteins and cell cycle dynamics.

Authors:  Vittoria Cenni; Cristina Capanni; Elisabetta Mattioli; Marta Columbaro; Manfred Wehnert; Michela Ortolani; Milena Fini; Giuseppe Novelli; Jessika Bertacchini; Nadir M Maraldi; Sandra Marmiroli; Maria Rosaria D'Apice; Sabino Prencipe; Stefano Squarzoni; Giovanna Lattanzi
Journal:  Aging (Albany NY)       Date:  2014-09       Impact factor: 5.682

5.  Prelamin A processing, accumulation and distribution in normal cells and laminopathy disorders.

Authors:  Andrea Casasola; David Scalzo; Vivek Nandakumar; Jessica Halow; Félix Recillas-Targa; Mark Groudine; Héctor Rincón-Arano
Journal:  Nucleus       Date:  2016       Impact factor: 4.197

Review 6.  Nuclear damages and oxidative stress: new perspectives for laminopathies.

Authors:  G Lattanzi; S Marmiroli; A Facchini; N M Maraldi
Journal:  Eur J Histochem       Date:  2012-10-18       Impact factor: 3.188

Review 7.  Different prelamin A forms accumulate in human fibroblasts: a study in experimental models and progeria.

Authors:  S Dominici; V Fiori; M Magnani; E Schena; C Capanni; D Camozzi; M R D'Apice; C Le Dour; M Auclair; M Caron; G Novelli; C Vigouroux; N M Maraldi; G Lattanzi
Journal:  Eur J Histochem       Date:  2009-03-31       Impact factor: 3.188

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.